Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

NCT00911820 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Gastric Cancer
Stomach Cancer

Interventions

DRUG: Bevacizumab
DRUG: Cisplatin
DRUG: Irinotecan
DEVICE: Docetaxel

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]